Cardiovascular Safety During Oncology Drug Development

来源 :亚太药物研发领袖峰会(Asia Pharma R&D Leaders Summit 2018) | 被引量 : 0次 | 上传用户:yiteng89
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
Were developing treatments for cancer Why worry about rare cardiac side effects?
其他文献
Radiation Detection Instruments (1)Scintillation Detector (ZnS(Ag))Treatment priority Medical treatment for serious conditions always take precedence over decon
会议
核事故医学应急面临的形式和任务1.核电站的发展:2.核燃料循环的发展:核电站的建设,带动了核燃料循环的快速发展,一批相应的核燃料生产设施和核废料后处理设施也要建设.3.核
会议
Outline· Past-There was no guidance in those early years -Mainly conducted BE trials of generic drugs -Generic PK trials of imported drugs requested by SFDA ·
会议
Contents 1.Brief history of pharmacometrics in China 1979-2000: PD, PK, statistical model 2000-2015: PPK, PK-PD, MBMA 2.China status of pharmacometrics only pre
会议
Outline · Trends in globalization of clinical drug development and ethnicity focused regulatory environment · Mechanisms for ethnic differences in drug respon
会议
Content 1.Use of PPK, PK/PD in clinical research of antimicrobial agents 2.PPK and PK/PD guide optimization of treatment regimen 3.PPK and PK/PD guide treatment
会议
·Drug development decision makers need In rely on robust rationale to select drug candidates, targets, trial designs, dose regimens, patient populations and su
会议
Cancer therapy PD of Irreversible Effects: Phase-nonspecific PD of Irreversible Effects: Phase-nonspecific PD of Irreversible Effects: Cell-cycle Specific
会议
BIODURO The Spring is here! The Spring of Drug Discovery in China is here Talents Policy Money Entrepreneurship Basic research
会议
致谢中国外商投资企业协会药品研制和开发行业委员会(RDPAC)的成员-默沙东中国有限公司,Wendy Yu-罗氏(中国)控股有限公司,Melly Lin
会议